Keyhole Limpet Hemocyanin

Summary

Keyhole Limpet Hemocyanin (CHEMBL5314988) is a phase-3 clinical-stage unknown; indicated across 12 conditions including lymphoma and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 12 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314988
Name	Keyhole Limpet Hemocyanin
Type	Unknown
Max phase	3

Also known as: Keyhole limpet hemocyanin, KEYHOLE LIMPET HEMOCYANIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lymphoma	3	MONDO:0005062	EFO:0000574
breast neoplasm	3	MONDO:0021100	MONDO:0007254
multiple sclerosis	3	MONDO:0005301	MONDO:0005301
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
kidney cancer	2	MONDO:0002367	MONDO:0002367
lung neoplasm	2	MONDO:0021117	MONDO:0008903
glioblastoma	2	MONDO:0018177	EFO:0000519
paraganglioma	2	MONDO:0000448	EFO:1000453
cutaneous melanoma	1	MONDO:0005012	EFO:0000389

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1	5
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003638	PHASE3	COMPLETED	Vaccine Therapy in Treating Women With Metastatic Breast Cancer
NCT00006034	PHASE3	COMPLETED	Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
NCT00017290	PHASE3	UNKNOWN	Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin’s Lymphoma
NCT00004197	PHASE2	COMPLETED	Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
NCT00004198	PHASE2	COMPLETED	Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin’s Lymphoma
NCT00004249	PHASE2	COMPLETED	Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy
NCT00006478	PHASE2	TERMINATED	Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin’s Lymphoma
NCT00019097	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Multiple Myeloma
NCT00093522	PHASE2	UNKNOWN	Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
NCT00282308	PHASE2	COMPLETED	A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
NCT00003819	PHASE1	COMPLETED	Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
NCT00091143	PHASE1	COMPLETED	Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
NCT00369291	PHASE1	TERMINATED	CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
NCT02079480	PHASE1	TERMINATED	Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects
NCT05845996	PHASE1	COMPLETED	Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).